Goldman Sachs' alternative investment arm announced Monday its plan to acquire a majority stake in Dutch drugmaker Synthon from British investment firm BC Partners LLP, in a deal valuing Synthon at €2 billion ($2.1 billion), including debt. BC Partners will retain a minority interest in the company, though specific ownership details were not disclosed.

Synthon’s Role in Generic Medicines

Synthon specializes in the development, manufacturing, and licensing of complex generic medicines aimed at increasing global access to affordable treatments. The company operates research and production facilities in the Czech Republic, Spain, Chile, and Argentina.

Adam Dawson, managing director at Goldman Sachs Alternatives, highlighted Synthon’s strong position in the generic drug market. "Synthon's expertise in complex drug development and manufacturing positions it to capitalize on the growing demand for affordable medicines globally," he said.

Anish Mehta, Synthon’s CEO, expressed optimism about the partnership. "The network, expertise, and combined resources of both firms will enable our continued growth and success," Mehta said.

BC Partners Retains Minority Stake

BC Partners, which acquired a majority stake in Synthon in 2019, will maintain a minority interest in the pharmaceutical company. The firm plans to continue supporting Synthon's expansion, citing past investments in technology, manufacturing, and geographic growth during its tenure as majority owner.

"Building on the great work of the founders, we have heavily invested in additional complex technologies and expanded manufacturing capabilities," said Mark Hersee, a partner at BC Partners.

Legal Advisors and Timeline

Goldman Sachs Alternatives is receiving legal counsel from White & Case LLP, Allen & Overy, Shearman & Sterling, and Sullivan & Cromwell LLP. Synthon is represented by Latham & Watkins LLP.

The transaction, expected to close by June 2025, is subject to customary regulatory and closing conditions.